February 3, 2015

DSN senior editor Michael Johnsen examines in-depth sales activity in the cough-cold categories, highlighting new products that are transforming OTC in this multi-page report.

January 5, 2015

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a Q&A with Owen Mumford's Travis Shaw, in this multi-page report.

January 5, 2015

DSN senior editor Michael Johnsen examines in-depth sales activity in the vitamins, minerals and supplements and diet aid categories, highlighting new products that are transforming OTC in this multi-page report.

December 12, 2014

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a look at FDA reform and its potential impact on healthcare costs, in this multi-page report.

December 5, 2014

DSN senior editor Michael Johnsen examines in-depth sales activity in analgesics, vitamins, allergy/cold/sinus medications, and incontinence, highlighting new products that are transforming OTC in this multi-page report.

November 18, 2014

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, as well as a look at the impact of the Hatch-Waxman act and Q&A's with industry leaders, in this multi-page report.

November 13, 2014

DSN senior editor Michael Johnsen examines in-depth sales activity in blood-pressure monitoring kits and blood-glucose meters, highlighting new products that are transforming OTC in this multi-page report.

October 10, 2014

DSN examines chain pharmacy, including in-depth coverage of pharmacy technology, biosimilars and generics, in this multi-page report.

October 10, 2014

DSN senior editor Michael Johnsen examines in-depth sales activity in analgesics and digestives, highlighting new products that are transforming OTC in this multi-page report.

September 16, 2014

DSN examines chain pharmacy, including in-depth coverage of Hispanic consumers and in-store testing, in this multi-page report.

September 16, 2014

DSN senior editor Michael Johnsen examines in-depth sales activity in homeopathy and foot care, highlighting new products that are transforming OTC in this multi-page report.

August 20, 2014

Adult incontinence and urinary bladder control represent one of the more lucrative categories in OTC, but it’s not necessarily the most talked-about category.

August 20, 2014

Merck Consumer Care’s Oxytrol for Women brings women with overactive bladder concerns to the self-care aisle for the first time.

August 19, 2014

Nearly half of women age 45 years or older who experience symptoms of overactive bladder report their current treatment does not address their OAB symptoms, according to a recent survey conducted by The Harris Poll on behalf of Allergan.

August 18, 2014

DSN examines chain pharmacy, including in-depth coverage of generics and technology, in this multi-page report.

August 18, 2014

DSN senior editor Michael Johnsen examines in-depth sales activity in pain, cough-cold, overactive bladder, allergy and more, highlighting new products that are transforming OTC in this multi-page report.

January 7, 2014

Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday.

September 26, 2013

Merck Consumer Care announced that Oxytrol for Women is now on shelf for the more than 20 million women suffering from overactive bladder.

August 8, 2013

The big news in incontinence is Oxytrol, which doesn't reach store shelves until September. It's a switched product coming from Merck Consumer Care that brings an entirely new indication to the over-the-counter space — overactive bladder in women.

July 3, 2013

Drug maker Impax Labs is hoping to become the first to market a generic version of a drug used to treat incontinence and overactive bladder, the company said Wednesday.

May 29, 2013

The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said.

January 25, 2013

Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area.

November 29, 2012

The Food and Drug Administration approved a new generic drug made by Mylan for urinary disorders, the company said Thursday.

November 15, 2012

The Food and Drug Administration's Nonprescription Drugs Advisory Committee on Friday voted against Merck's application to switch its Oxytrol patch from prescription-only to over the counter, citing concerns over use of therapy for an overactive bladder in women without a doctor's intervention.